A study finds that people with uncontrolled epilepsy ? neurological disorder ? resort to cannabis products when antiepileptic drug side-effects are intolerable. Epilepsy is a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. University of Sydney researchers revealed that 14 percent of people with epilepsy have used cannabis products as a way to manage seizures.
Intense abnormal activity in well-known brain networks that occurs early in a seizure may be the key to impaired consciousness in children with absence epilepsy, new research suggests.
New open-label data from the expanded-access treatment program involving the cannabidiol Epidiolex (GW Pharma) show the median reduction in frequency of convulsive seizures after 3 months of treatment was 45% in all patients but higher in those with Dravet syndrome, among the most severe types of epilepsy. The data are “very positive and promising,” said lead author Orrin Devinsky, MD, professor, neurology, neurosurgery and psychiatry, and director, New York University Comprehensive Epilepsy Center.
Date: August 23, 2016 Source: Linköping University Summary: Researchers have developed in collaboration with French colleagues a small device that both detects the initial signal of an epileptic attack and doses a substance that effectively stops it. All this takes place where the signal arises — in an area of size 20chr(‘215’)20 μm known as a ‘neural pixel.’ The bioelectronic neural pixel: Chemical stimulation and electrical sensing at the same site Researchers at Linköping University have developed in collaboration with French colleagues a small device that both detects the initial signal of an epileptic attack and doses a substance that effectively stops it. All this takes place where the signal arises — in an area of size 20×20 μm known as a “n...
After 2 years of delays, appeals and uncertainty about availability, high-CBD, low-THC Medical Cannabis grown in Florida will finally be available next week to patients with prescriptions. Trulieve, located in Tallahassee, Florida, have announced that they have received the first formal authorization from the Florida DOH (Department of Health) to commence sales and dispensary of medicinal cannabis products. These CBD products are approved for persons with uncontrollable seizures and cancer and possibly other conditions. Children with Dravet syndrome and intractable and other hard-to-treat types of Epilepsy are expected to be greatly helped by the availability of high-CBD cannabis derived medicine. For more information check out Orlando Weekly, Miami Herald, or Orlando Sentinel and many oth...
In this interview, Dr. Andrew N. Wilner, MD, interviews Dr. Joseph F. Drazkowski, MD who is involved with the American Academy of Neurology developing courses for neurologists, for increasing proficiency in EEG and EEG video. Excerpt from Medscape:
Despite currently being the most promising drug for the treatment of Dravet Syndrome, CBD still faces a lot of challenges. Retrospective studies and preliminary evidence from clinical trials suggest that Cannabidiol (CBD) might be effective in reducing seizures in some paediatric epilepsy syndromes. One condition in particular – Dravet syndrome, or myoclonic epilepsy of infancy, has gathered a great level of interest from the medical and pharmaceutical communities in relation to CBD treatment.
While extensive anecdotal exists for CBD as a treatment for adult epilepsy, more peer-reviewed research is still needed. Epileptic seizures are abnormal patterns of electrical activity in the nervous system. They can vary in intensity and frequency, causing side effects that range from mild to life-threatening, such as sensory perturbations, convulsions, and loss of consciousness. It is estimated that epilepsy affects close to 0.7 percent of the world population, with nearly two hundred thousand patients in Canada and three million in the U.S.A. This makes it one of the most common neurological disorders, only surpassed in prevalence by migraine, stroke and dementias.
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, has announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy. Epilepsy occurs in around 80-90% of TSC patients and is a significant cause of morbidity and mortality. TSC is the third indication that GW is targeting within its Epidiolex clinical development program, which includes four Phase 3 pivotal trials in Dravet syndrome and Lennox-Gastaut syndrome, both rare and catastrophic forms of childhood-onset epil...
A team of researchers have said that they might be able to use cannabis-based products to treat Epilepsy effectively. The researchers at the Comprehensive Epilepsy Center at NYU Langone Medical Centersaid that they might use extracts from marijuana to offer treatment of the disease. They are using a liquid form of cannabidiol, which is one of the key compounds of marijuana. The medicine is currently undergoing clinical trials in the United States and some other countries. They are aiming to study the effectiveness of the experimental medicine, called Epidiolex.